Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal

Launched by ADOCIA · Jan 19, 2015

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 1 Diabetes Mellitus ≥ 12 months
• • Treated with multiple daily insulin injections or CSII ≥ 12 months
• • BMI 18.5-28.0 kg/m² (both inclusive)
• • HbA1C%≤9%
• Exclusion Criteria:
• • Type 2 Diabetes Mellitus
• • Receipt of any trial product within 60 days prior to this trial
• • Clinically significant abnormal haematology, biochemistry, lipids or urinalysis screening tests as judged by the investigator considering the underlying disease
• • Presence of clinically significant acute gastroinstestinal symptoms as judged by the investigator
• • Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption.
• • Any systemic treatment with drugs known to interfere with glucose metabolism
• • Use of any tobacco or nicotine-contained product within one year prior to screening